Herbs (Global Traditional) · Traditional Chinese Medicine
Epimedium (Epimedium grandiflorum) (Epimedium grandiflorum)
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Epimedium grandiflorum is a traditional Chinese medicinal herb containing the bioactive compound icariin, which inhibits PDE5 enzymes and enhances nitric oxide signaling. The herb demonstrates potential effects on bone health, reproductive function, and cellular antioxidant activity.
Epimedium grandiflorum, commonly known as horny goat weed, is a perennial herbaceous plant native to Asia, particularly China, belonging to the Berberidaceae family. The medicinal parts are primarily the leaves, from which bioactive compounds are extracted using aqueous or ethanol-based processes.
No human clinical trials, RCTs, or meta-analyses were found for Epimedium grandiflorum. Evidence is limited to preclinical in vitro studies using MC3T3-E1 osteoblast cells and in vivo animal studies in rats and mice, with no PubMed PMIDs available for human studies.
No clinically studied human dosages available. Preclinical data: aqueous extract at 6.25 μg/mL in vitro; 0.81-2.43 g/kg/day in rats; icariin at 10-100 μM in cell studies. Consult a healthcare provider before starting any new supplement.
Epimedium grandiflorum is not consumed as a food source and does not provide meaningful macronutrient content (negligible protein, fat, and carbohydrate in typical supplemental doses of 250–1000 mg/day). Its nutritional significance lies primarily in its bioactive phytochemical profile: **Flavonoids (primary active constituents):** Icariin is the principal bioactive flavonol glycoside, typically comprising 5–20% of standardized dry extract by weight (equivalent to ~50–200 mg icariin per gram of standardized extract); commercial preparations are often standardized to ≥10% icariin. Icariside I and Icariside II (metabolic derivatives of icariin) are present at lower concentrations (~1–5% of extract). Epimedin A, B, and C are co-occurring prenylated flavonol glycosides at approximately 2–8% combined. Baohuoside I (also called icariside II in some literature) contributes additional PDE5-inhibitory activity. **Polysaccharides:** Epimedium polysaccharides (EPS) are present at roughly 3–8% of dry herb weight and are associated with immunomodulatory activity. **Phenolic acids:** Trace amounts of quercetin and kaempferol aglycones are found after hydrolysis of glycoside forms. **Sterols and lignans:** Beta-sitosterol and small quantities of magnoflorine (an alkaloid) have been identified at <1% dry weight. **Minerals:** Calcium (~12–18 mg/g dry herb), magnesium (~2–4 mg/g), zinc (~0.03–0.06 mg/g), and iron (~0.1–0.2 mg/g) have been detected, though these are pharmacologically insignificant at typical supplemental doses. **Bioavailability notes:** Icariin itself has poor oral bioavailability (~1–2%) due to limited intestinal absorption; gut microbiota and intestinal enzymes hydrolyze icariin to the more bioavailable icariside II and icaritin, which demonstrate substantially higher membrane permeability and plasma detection. Fat-soluble flavonoid fractions may benefit from co-administration with lipids. Standardized extracts with ≥40% total flavonoids as icariin are used in clinical research contexts to improve dose consistency.
Epimedium's primary bioactive compound icariin acts as a phosphodiesterase-5 (PDE5) inhibitor, enhancing cGMP levels and nitric oxide signaling pathways. The herb enhances osteoblast activity while reducing HIF-1α gene expression in bone tissue. Icariin also modulates Sertoli cell function and supports cellular antioxidant defense mechanisms through free radical scavenging.
Current evidence for epimedium primarily comes from preliminary cell culture studies and animal research rather than human clinical trials. Animal studies using doses of 0.81-2.43 g/kg/day demonstrated antioxidant effects, though human equivalent dosing remains unclear. Cell studies show promising effects on bone cell activity and reproductive tissue function, but these findings require validation in controlled human studies. The limited clinical evidence prevents definitive conclusions about therapeutic efficacy in humans.
Epimedium may cause side effects including dizziness, nausea, and potential hormonal fluctuations due to its phytoestrogen content. The herb may interact with blood pressure medications and anticoagulants due to its vasodilatory effects. Safety during pregnancy and breastfeeding is unknown, making it contraindicated for pregnant women. Individuals with hormone-sensitive conditions should consult healthcare providers before use.
